Pieris Pharmaceuticals (PIRS) Stock Forecast, Price & News

Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

Is Pieris Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pieris Pharmaceuticals stock.
View analyst ratings for Pieris Pharmaceuticals or view top-rated stocks.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Pieris Pharmaceuticals.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.05. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 93.41% and a negative net margin of 175.99%. During the same period in the previous year, the company posted ($0.07) earnings per share.
View Pieris Pharmaceuticals' earnings history.

What price target have analysts set for PIRS?

2 analysts have issued twelve-month price objectives for Pieris Pharmaceuticals' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 373.4% from the stock's current price.
View analysts' price targets for Pieris Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the following people:

• Mr. Stephen S. Yoder, CEO, Pres & Director (Age 46, Pay $730.13k)
• Mr. Thomas Bures, Sr. VP & CFO (Age 48, Pay $360.51k)
• Dr. Hitto Kaufmann Ph.D., Sr. VP & Chief Scientific Officer (Age 51, Pay $458.68k)
• Maria Kelman, Exec. Director of Investor Relations
• Mr. Ahmed S. Mousa J.D., Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec. (Age 38)
• Mr. Frank Vollmering, VP of HR
• Dr. Christine Rothe Ph.D., VP and Head of Early Stage Project Leadership & Data Science
• Dr. Shane Olwill Ph.D., Sr. VP & Chief Devel. Officer
• Mr. Prompong Chaikul, Chief Supply Chain Officer (Age 35)
• Dr. Tim Demuth M.D., Ph.D., Sr. VP & Chief Medical Officer

Who are some of Pieris Pharmaceuticals' key competitors?

Some companies that are related to Pieris Pharmaceuticals include Praxis Precision Medicines (PRAX), ANI Pharmaceuticals (ANIP), ADC Therapeutics (ADCT), Day One Biopharmaceuticals (DAWN), Centessa Pharmaceuticals (CNTA), Amylyx Pharmaceuticals (AMLX), Foghorn Therapeutics (FHTX), Mawson Infrastructure Group (WIZP), Nkarta (NKTX), CTI BioPharma (CTIC), Cara Therapeutics (CARA), 2seventy bio (TSVT), Tango Therapeutics (TNGX), Arcturus Therapeutics (ARCT) and Kinnate Biopharma (KNTE).
View all of PIRS's competitors.

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL).

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Woodline Partners LP (2.14%), BlackRock Inc. (1.81%), Assenagon Asset Management S.A. (1.63%), Citigroup Inc. (0.65%), Healthcare of Ontario Pension Plan Trust Fund (0.56%) and Cutter & CO Brokerage Inc. (0.55%). Company insiders that own Pieris Pharmaceuticals stock include Aquilo Capital Management, Llc, Shane Olwill and Tim Demuth.
View institutional ownership trends for Pieris Pharmaceuticals.

Which major investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Goldman Sachs Group Inc., Assenagon Asset Management S.A., Connor Clark & Lunn Investment Management Ltd., Citigroup Inc., Group One Trading L.P., and Simplex Trading LLC.
View insider buying and selling activity for Pieris Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Pieris Pharmaceuticals stock?

PIRS stock was bought by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, JPMorgan Chase & Co., Renaissance Technologies LLC, State Street Corp, UBS Group AG, BlackRock Inc., Commerce Bank, and Bailard Inc..
View insider buying and selling activity for Pieris Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $1.69.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals has a market capitalization of $125.23 million and generates $31.42 million in revenue each year. The biotechnology company earns $-45.74 million in net income (profit) each year or ($0.69) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

Pieris Pharmaceuticals employs 124 workers across the globe.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is www.pieris.com.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at (857) 246-8998, via email at [email protected], or via fax at 49-8161-141-1444.